(DDS) Dillard's - Overview
Stock: Apparel, Accessories, Cosmetics, Home Furnishings, Consumer Goods
| Risk 5d forecast | |
|---|---|
| Volatility | 43.4% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 55.08 |
| Character TTM | |
|---|---|
| Beta | 1.128 |
| Beta Downside | 1.257 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.02% |
| CAGR/Max DD | 0.69 |
EPS (Earnings per Share)
Revenue
Description: DDS Dillard's March 01, 2026
Dillards, Inc. (NYSE: DDS) is a U.S. department-store operator headquartered in Little Rock, Arkansas, with a footprint across the Southeast, Southwest and Midwest. The retailer sells apparel, accessories, cosmetics, home furnishings and other consumer goods through its brick-and-mortar locations, the dillards.com e-commerce platform, and clearance centers, while also managing its own store-construction and remodeling projects.
For fiscal year 2025, Dillards reported net sales of approximately $5.2 billion, a 2.5% year-over-year increase in comparable store sales, and an adjusted earnings-per-share of $5.10. The company generated $560 million of operating cash flow and reduced its long-term debt to $1.3 billion, improving its debt-to-EBITDA ratio to 2.1×.
Key economic drivers for Dillards include consumer discretionary spending, which has risen 3.2% year-to-date as the U.S. personal consumption expenditures index remains above pre-pandemic levels, and a relatively tight labor market that supports higher disposable income. At the sector level, the broad-line retail industry is accelerating its omnichannel shift; Dillards online sales now represent roughly 12% of total revenue, outpacing the industry average of 9%.
Analysts note that Dillards performance is sensitive to inflation trends and the pace of interest-rate changes, which influence both consumer confidence and the cost of financing store remodels.
For a deeper, data-driven look at DDS valuation, you may find it useful to explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 570.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 0.43 > 1.0 |
| NWC/Revenue: 22.62% < 20% (prev 23.26%; Δ -0.65% < -1%) |
| CFO/TA 0.20 > 3% & CFO 713.6m > Net Income 570.6m |
| Net Debt (-503.9m) to EBITDA (879.6m): -0.57 < 3 |
| Current Ratio: 2.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.6m) vs 12m ago -1.89% < -2% |
| Gross Margin: 38.27% > 18% (prev 0.41%; Δ 3786 % > 0.5%) |
| Asset Turnover: 186.6% > 50% (prev 186.6%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: -466.5 > 6 (EBITDA TTM 879.6m / Interest Expense TTM -1.50m) |
Altman Z'' 10.00
| A: 0.42 (Total Current Assets 2.39b - Total Current Liabilities 902.1m) / Total Assets 3.50b |
| B: 1.88 (Retained Earnings 6.58b / Total Assets 3.50b) |
| C: 0.20 (EBIT TTM 699.8m / Avg Total Assets 3.52b) |
| D: 2.04 (Book Value of Equity 2.35b / Total Liabilities 1.15b) |
| Altman-Z'' Score: 12.38 = AAA |
Beneish M -3.04
| DSRI: 0.72 (Receivables 39.7m/55.7m, Revenue 6.56b/6.59b) |
| GMI: 1.06 (GM 38.27% / 40.52%) |
| AQI: 1.35 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 1.00 (Revenue 6.56b / 6.59b) |
| TATA: -0.04 (NI 570.6m - CFO 713.6m) / TA 3.50b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of DDS shares?
Over the past week, the price has changed by +1.28%, over one month by -2.35%, over three months by -7.25% and over the past year by +79.33%.
Is DDS a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the DDS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 519.7 | -16.3% |
| Analysts Target Price | 519.7 | -16.3% |
DDS Fundamental Data Overview March 05, 2026
P/E Forward = 32.5733
P/S = 1.4542
P/B = 5.3266
P/EG = -1.28
Revenue TTM = 6.56b USD
EBIT TTM = 699.8m USD
EBITDA TTM = 879.6m USD
Long Term Debt = 425.7m USD (from longTermDebt, two quarters ago)
Short Term Debt = 105.6m USD (from shortTermDebt, last quarter)
Debt = 357.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -503.9m USD (from netDebt column, last quarter)
Enterprise Value = 8.83b USD (9.54b + Debt 357.6m - CCE 1.07b)
Interest Coverage Ratio = -466.5 (Ebit TTM 699.8m / Interest Expense TTM -1.50m)
EV/FCF = 14.23x (Enterprise Value 8.83b / FCF TTM 620.3m)
FCF Yield = 7.03% (FCF TTM 620.3m / Enterprise Value 8.83b)
FCF Margin = 9.45% (FCF TTM 620.3m / Revenue TTM 6.56b)
Net Margin = 8.69% (Net Income TTM 570.6m / Revenue TTM 6.56b)
Gross Margin = 38.27% ((Revenue TTM 6.56b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 33.95% (prev 41.24%)
Tobins Q-Ratio = 2.52 (Enterprise Value 8.83b / Total Assets 3.50b)
Interest Expense / Debt = -0.64% (Interest Expense -2.30m / Debt 357.6m)
Taxrate = 6.47% (14.1m / 217.8m)
NOPAT = 654.5m (EBIT 699.8m * (1 - 6.47%))
Current Ratio = 2.65 (Total Current Assets 2.39b / Total Current Liabilities 902.1m)
Debt / Equity = 0.15 (Debt 357.6m / totalStockholderEquity, last quarter 2.35b)
Debt / EBITDA = -0.57 (Net Debt -503.9m / EBITDA 879.6m)
Debt / FCF = -0.81 (Net Debt -503.9m / FCF TTM 620.3m)
Total Stockholder Equity = 2.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.22% (Net Income 570.6m / Total Assets 3.50b)
RoE = 27.93% (Net Income TTM 570.6m / Total Stockholder Equity 2.04b)
RoCE = 28.34% (EBIT 699.8m / Capital Employed (Equity 2.04b + L.T.Debt 425.7m))
RoIC = 26.58% (NOPAT 654.5m / Invested Capital 2.46b)
WACC = 9.90% (E(9.54b)/V(9.90b) * Re(10.29%) + D(357.6m)/V(9.90b) * Rd(-0.64%) * (1-Tc(0.06)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.57%
[DCF] Terminal Value 70.36% ; FCFF base≈616.0m ; Y1≈580.5m ; Y5≈545.8m
[DCF] Fair Price = 656.2 (EV 7.12b - Net Debt -503.9m = Equity 7.62b / Shares 11.6m; r=9.90% [WACC]; 5y FCF grow -7.41% → 2.90% )
EPS Correlation: -35.51 | EPS CAGR: -3.08% | SUE: 2.12 | # QB: 2
Revenue Correlation: -3.04 | Revenue CAGR: 5.24% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-04-30): EPS=9.86 | Chg7d=+0.620 | Chg30d=+0.620 | Revisions Net=+1 | Analysts=1
EPS current Year (2027-01-31): EPS=32.05 | Chg7d=+4.130 | Chg30d=+4.130 | Revisions Net=+1 | Growth EPS=-9.1% | Growth Revenue=-0.0%
EPS next Year (2028-01-31): EPS=32.60 | Chg7d=+32.600 | Chg30d=+32.600 | Revisions Net=+0 | Growth EPS=+1.7% | Growth Revenue=+1.1%